Humacyte, Inc. (HUMA) Technical Analysis & Indicators

Humacyte, Inc. (HUMA) — Price $0.57 HealthcareBiotechnology — NASDAQ

Latest reported results:

Technical analysis of Humacyte, Inc. (HUMA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).

Price Performance

1 month-2.01%
3 months-38.34%
Year-to-date-40.66%
1 year-62.75%
3 years-81.31%
5 years-96.01%

52-Week Range

52-week High$2.55
52-week Low$0.53
Avg Volume (90d)9.7M

Technical Indicators

SMA 50$0.65
SMA 200$0.92
Beta2.10
30-day Volatility (annualised)111.1%
Price vs SMA 50-12.0%
Price vs SMA 200-37.8%

Monthly Close (12 months)

MonthCloseChange
2025-10$1.67
2025-11$1.35-19.2%
2025-12$0.96-28.9%
2026-01$1.00+3.9%
2026-02$1.12+12.3%
2026-03$0.61-45.8%
2026-04$0.84+38.8%
2026-05$1.30+54.4%
2026-06$0.78-40.0%
2026-07$0.65-16.3%
2026-08$0.60-8.0%
2026-09$0.57-5.2%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-09-14$-2.53
2026-09-14$159M
2026-09-14$-0.26$14M
2026-09-14
2026-09-14$0.84$26M
2026-09-14

Price

Price$0.57
Market Cap$96M
ExchangeNASDAQ
CountryUS

Valuation Ratios

Price / Book4.30
EV / EBITDA-1.10
Dividend Yield0.00%

Financial Health

Debt / Equity2.12
Current Ratio6.21
Piotroski F-Score4
Altman Z-Score-10.46

Related companies: ACHV · ARCT · AVIR · FHTX · IMRX · NAUT · SGMT

Explore sector: Healthcare · Biotechnology

More sections of HUMA: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks